Showing 991-1000 of 9460 results for "".
AAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAUnderstanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/understanding-the-effect-of-targeting-il-17af-in-psoriatic-arthritis/56663/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Naeim T. Issa, MD, PhD, FAAD, continue their discussion of the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective,” focusinTips and Tricks for Prescribing Biologics for Pediatric Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/tips-and-tricks-for-prescribing-biologics-for-pediatric-patients/54662/Dawn Eichenfield, MD, PhD, discusses key takeaways from the “Pediatric Dermatology 2026” session at Maui Derm Hawaii 2026.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 2
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-2/32758/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss the differences between psoriasis subtypes, the importance of a specialized therapeutic approach targeting the IL-36 pathway for generalized pustular psoriasis, and the role of neutrophiPatient Perspectives on Unmet Needs in Topical Psoriasis Therapy
https://practicaldermatology.com/issues/january-february-2025/patient-perspectives-on-unmet-needs-in-topical-psoriasis-therapy/32972/Despite the advantages of topical treatment, nonadherence (including overuse and underuse) affects up to 50% of patients, and therapy overuse is often incited by the desire for rapid clearance, ineffectiveness, and unclear instructions.ISDPA: Society Leadership Discusses Issues Facing PAs
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-society-leadership-discusses-issues-facing-pas/27067/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about the latest issues facing physicians assistants with Illinois Society of Dermatology Physician Assistants (ISDPA) leaders Jang-Mi Johnson, PA-C; Sarah Anderson, PA-C; Jordan Stemer, PA-C; and Andrew Mastro, PA-C, at the ISDPsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Noah Worcester 2024: Dr. Bar on Surgical Procedures
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bar-surgical-procedures/24592/Anna Bar, MD, summarizes her lectures on surgical procedures at the 2024 Noah Worcester Dermatological Society meeting.Noah Worcester 2024: AAD President Dr. Desai on the AAD
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-desai-aad/24589/Seemal Desai, MD, FAAD, president of the American Academy of Dermatology, summarizes his AAD update presentation at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: ASDS Meeting Highlights; Daxxify Data; PA Week
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-asds-meeting-highlights-daxxify-data-pa-week/20147/ASDS speakers address aesthetic advancements, skin cancer, and DEI with Joel L. Cohen, MD, Sherrif Ibrahim, MD, and Jeanine Downie, MD. On the heels of FDA approval of Revance’s Daxxify, data published in the Aesthetic Surgery Journal demonstrate the efficacy of DaxibotulinumtoxinA for patients of d